1273663-71-0

Basic information

• Product Name: 4-SULFANYL-2,3-DIHYDRO-1H-INDEN-1-ONE
• Synonyms: 4-SULFANYL-2,3-DIHYDRO-1H-INDEN-1-ONE
• CAS NO: 1273663-71-0
• Molecular Formula: C9H8OS
• Molecular Weight: 164.22422
• Mol File: 1273663-71-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-SULFANYL-2,3-DIHYDRO-1H-INDEN-1-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-SULFANYL-2,3-DIHYDRO-1H-INDEN-1-ONE(1273663-71-0)
• EPA Substance Registry System: 4-SULFANYL-2,3-DIHYDRO-1H-INDEN-1-ONE(1273663-71-0)

Safety Data

• Hazardous Substances Data: 1273663-71-0(Hazardous Substances Data)

Upstream product

• 15115-60-3 4-bromo-2,3-dihydroinden-1-one 

Relevant articles and documents

Novel 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as potent selective human monoamine oxidase B inhibitors: Design, SAR development, and biological evaluation

Successes have been achieved in developing human monoamine oxidase B (hMAO-B) inhibitors as anti-Parkinson's disease (PD) drugs. However, low efficiency and unwanted side effects of the marketed hMAO-B inhibitors hamper their medical applications, therefore, novel potent selective hMAO-B inhibitors are still of great interest. Herein we report 1-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-indene-4-thiol derivatives as hMAO-B inhibitors, which were designed by employing a fragment-based drug design strategy to link rasagiline to hydrophobic fragments. Among the synthesized 31 compounds, K8 and K24 demonstrated very encouraging hMAO-B inhibitory activities and selectivity over hMAO-A, better than rasagiline and safinamide. In vitro studies indicated that K8 and K24 are nontoxic to nervous tissue cells and they have considerable effects against ROS formation and potential neuroprotective activity. Further mice behavioral tests demonstrated these two compounds have good therapeutic effects on MPTP-induced PD model mice. All these experiment results suggest that compounds K8 and K24 can be promising candidates for further research for treatment of PD.

NEW INDANYLOXYPHENYLCYCLOPROPANECARBOXYLIC ACIDS

The present invention relates to compounds of general formula (I), wherein the groups R1, R2, R3, X, m and n are defined as in claim 1, wich have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.